液体活检在结直肠癌微小残留病灶检测中的研究及应用进展  

Research and Application Progress of Liquid Biopsy in Detecting Minimal Residual Disease of Colorectal Cancer

作　　者：何宗杰 李雪莹 白辰光 He Zongjie;Li Xueying;Bai Chenguang(Department of Pathology,the First Affiliated Hospital of Naval Medical University,Shanghai 200433,China)

机构地区：[1]海军军医大学第一附属医院病理科,上海200433

出　　处：《肿瘤预防与治疗》2024年第7期605-611,共7页Journal of Cancer Control And Treatment

基　　金：上海市“科技创新行动计划”医学创新研究专项(编号:21Y11912900)。

摘　　要：微小残留病灶是患者在接受治疗期间或治疗后,仍存在于患者体内、影像学无法检出的少量肿瘤细胞或者微小病灶,是肿瘤复发的首要原因。近年来液体活检作为一种新型的生物分子技术,通过提取患者体液分析癌症发生和发展过程中体内代谢物种类和数量的变化,有助于发现癌症新型生物标志物,以揭示疾病发展趋势,为癌症管理和治疗提供新的视角和维度。本文总结了液体活检在结直肠癌中的研究及应用,以及它们对患者预后的影响及治疗前景。Minimal residual disease is a small number of tumor cells or tiny lesions that still exist in the patient during or after treatment and cannot be detected by imaging,which is the primary cause of tumor recurrence.In recent years,as a new type of biomolecular technology,liquid biopsy can help to find new biomarkers for cancer,reveal disease development trends,and provide a new perspective and dimension for cancer management and treatment by extracting the patient's body fluid and analyzing the changes in the type and quantity of metabolites in the body during the occurrence and development of cancer.This article summarizes the research and application of liquid biopsy in colorectal cancer,as well as their impact on prognosis and treatment prospects.

关 键 词：液体活检 微小残留病灶 循环肿瘤DNA 循环肿瘤细胞 细胞外囊泡 

分 类 号：R735.3[医药卫生—肿瘤]